FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Allegion Plc

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target by $12 to $200 on an average of a forward P/E of 18x our 2027 EPS view of $9.45 (-$0.12), which yields $170, and our DCF model, assuming a terminal growth rate of 2.5%, WACC of 5.7% and 10-year FCFF CAGR of 18.2%, which yields $230. We lower our 2026 EPS estimate by $0.06 to $8.80. Although ALLE missed Q1 estimates, we keep our Strong Buy view due to strong execution fundamentals and attractive growth prospects, supported by sales expansion and margin improvement. We see continued sales and margin growth in 2026/2027, led by ALLE's electronics portfolio (up low double digits with secular tailwinds from smart building adoption), accretive M&A, and strength in nonresidential markets, particularly data centers, hospitality, office, and health care markets (~75% of ALLE's revenue base). Strong cash flow and a healthy balance sheet underpin our view. ALLE is demonstrating defensive characteristics through aftermarket exposure and growth potential through technology adoption.

Related Articles

Research

Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.

$BIO
Insider Trading

Comfort Systems USA Insider Sold Shares Worth $889,890, According to a Recent SEC Filing

Pablo G. Mercado, Director, on April 30, 2026, sold 500 shares in Comfort Systems USA (FIX) for $889,890. Following the Form 4 filing with the SEC, Mercado has control over a total of 3,000 common shares of the company, with 3,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035983/000153524626000004/xslF345X05/form4-05012026_040501.xml

$FIX
Insider Trading

Kaiser Aluminum Insider Sold Shares Worth $524,757, According to a Recent SEC Filing

Keith Harvey, Director, President & CEO, on April 29, 2026, sold 3,031 shares in Kaiser Aluminum (KALU) for $524,757. Following the Form 4 filing with the SEC, Harvey has control over a total of 94,308 common shares of the company, with 94,308 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/811596/000119312526201545/xslF345X05/ownership.xml

$KALU